2022 Q4 Form 10-Q Financial Statement
#000156459022036772 Filed on November 04, 2022
Income Statement
| Concept | 2022 Q4 | 2022 Q3 | 2021 Q3 |
|---|---|---|---|
| Revenue | $31.38M | $25.68M | $5.370M |
| YoY Change | 224.52% | 378.27% | -24.27% |
| Cost Of Revenue | $10.67M | $7.568M | $1.597M |
| YoY Change | 297.91% | 373.89% | -22.1% |
| Gross Profit | $20.70M | $18.12M | $3.773M |
| YoY Change | 196.35% | 380.12% | -25.11% |
| Gross Profit Margin | 65.99% | 70.53% | 70.26% |
| Selling, General & Admin | $21.73M | $16.85M | $10.34M |
| YoY Change | 81.05% | 63.05% | 88.25% |
| % of Gross Profit | 104.94% | 93.02% | 273.92% |
| Research & Development | $5.756M | $6.808M | $5.163M |
| YoY Change | -8.84% | 31.86% | 24.11% |
| % of Gross Profit | 27.8% | 37.58% | 136.84% |
| Depreciation & Amortization | $1.285M | $891.0K | $455.0K |
| YoY Change | 175.75% | 95.82% | 13.75% |
| % of Gross Profit | 6.21% | 4.92% | 12.06% |
| Operating Expenses | $27.48M | $23.66M | $15.50M |
| YoY Change | 50.06% | 52.66% | 60.6% |
| Operating Profit | -$6.779M | -$5.544M | -$11.73M |
| YoY Change | -40.16% | -52.72% | 154.34% |
| Interest Expense | $78.00K | $787.0K | -$1.228M |
| YoY Change | -105.9% | -164.09% | 161.28% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$1.863M | -$1.228M | |
| YoY Change | 51.71% | ||
| Pretax Income | -$6.701M | -$7.407M | -$12.95M |
| YoY Change | -47.03% | -42.82% | 154.98% |
| Income Tax | $19.00K | $19.00K | $9.000K |
| % Of Pretax Income | |||
| Net Earnings | -$6.720M | -$7.426M | -$12.96M |
| YoY Change | -46.95% | -42.71% | 154.76% |
| Net Earnings / Revenue | -21.42% | -28.91% | -241.38% |
| Basic Earnings Per Share | -$0.25 | -$0.47 | |
| Diluted Earnings Per Share | -$0.21 | -$0.25 | -$467.9K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 31.92M | 28.09M | 27.70M |
| Diluted Shares Outstanding | 30.23M | 27.70M |
Balance Sheet
| Concept | 2022 Q4 | 2022 Q3 | 2021 Q3 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $201.2M | $204.5M | $102.9M |
| YoY Change | 117.63% | 98.79% | -22.49% |
| Cash & Equivalents | $201.2M | $204.5M | $22.50M |
| Short-Term Investments | $0.00 | $0.00 | $80.36M |
| Other Short-Term Assets | $2.896M | $5.514M | $3.703M |
| YoY Change | -46.96% | 48.91% | 61.0% |
| Inventory | $20.61M | $18.58M | $14.87M |
| Prepaid Expenses | |||
| Receivables | $27.61M | $22.04M | $4.150M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $252.3M | $250.6M | $125.6M |
| YoY Change | 112.54% | 99.55% | -18.51% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $19.22M | $18.47M | $5.063M |
| YoY Change | 95.34% | 264.84% | 7.72% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $500.0K | $500.0K | $506.0K |
| YoY Change | 0.0% | -1.19% | 1.2% |
| Total Long-Term Assets | $24.85M | $24.29M | $5.569M |
| YoY Change | 53.53% | 336.11% | 7.1% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $252.3M | $250.6M | $125.6M |
| Total Long-Term Assets | $24.85M | $24.29M | $5.569M |
| Total Assets | $277.1M | $274.9M | $131.1M |
| YoY Change | 105.46% | 109.59% | -17.67% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $3.341M | $3.080M | $2.682M |
| YoY Change | -49.77% | 14.84% | 235.25% |
| Accrued Expenses | $20.08M | $17.38M | $12.77M |
| YoY Change | 22.91% | 36.13% | 11.03% |
| Deferred Revenue | $241.0K | $226.0K | |
| YoY Change | -3.6% | ||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $23.66M | $20.69M | $15.92M |
| YoY Change | 1.82% | 29.93% | 17.08% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $58.70M | $58.54M | $35.06M |
| YoY Change | 66.76% | 66.98% | 1.54% |
| Other Long-Term Liabilities | $7.415M | $7.787M | $1.616M |
| YoY Change | -13.82% | 381.87% | 1.0% |
| Total Long-Term Liabilities | $58.70M | $58.54M | $35.06M |
| YoY Change | 66.76% | 66.98% | 1.54% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $23.66M | $20.69M | $15.92M |
| Total Long-Term Liabilities | $58.70M | $58.54M | $35.06M |
| Total Liabilities | $89.77M | $87.02M | $52.60M |
| YoY Change | 33.91% | 65.44% | 5.68% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$478.7M | -$472.0M | -$429.8M |
| YoY Change | 8.19% | 9.82% | 9.67% |
| Common Stock | $666.3M | $660.1M | |
| YoY Change | 30.52% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $187.4M | $187.9M | $78.55M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $277.1M | $274.9M | $131.1M |
| YoY Change | 105.46% | 109.59% | -17.68% |
Cashflow Statement
| Concept | 2022 Q4 | 2022 Q3 | 2021 Q3 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$6.720M | -$7.426M | -$12.96M |
| YoY Change | -46.95% | -42.71% | 154.76% |
| Depreciation, Depletion And Amortization | $1.285M | $891.0K | $455.0K |
| YoY Change | 175.75% | 95.82% | 13.75% |
| Cash From Operating Activities | -$4.035M | -$14.28M | -$9.350M |
| YoY Change | -39.31% | 52.75% | 45.87% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $2.764M | -$2.930M | -$68.00K |
| YoY Change | -186.97% | 4208.82% | 36.0% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $0.00 | $27.68M | $6.267M |
| YoY Change | -100.0% | 341.65% | -126.76% |
| Cash From Investing Activities | -$2.764M | $24.75M | $6.199M |
| YoY Change | -127.66% | 299.23% | -126.41% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 3.065M | 164.2M | 552.0K |
| YoY Change | 6711.11% | 29650.0% | -406.67% |
| NET CHANGE | |||
| Cash From Operating Activities | -4.035M | -14.28M | -9.350M |
| Cash From Investing Activities | -2.764M | 24.75M | 6.199M |
| Cash From Financing Activities | 3.065M | 164.2M | 552.0K |
| Net Change In Cash | -3.734M | 174.7M | -2.599M |
| YoY Change | -210.18% | -6821.28% | -91.35% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$4.035M | -$14.28M | -$9.350M |
| Capital Expenditures | $2.764M | -$2.930M | -$68.00K |
| Free Cash Flow | -$6.799M | -$11.35M | -$9.282M |
| YoY Change | 95.94% | 22.3% | 45.94% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2021Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.47 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.03 | ||
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
27564589 | ||
| us-gaap |
Cost Of Revenue
CostOfRevenue
|
17515000 | ||
| dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
| CY2021Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2022 | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| CY2021Q4 | us-gaap |
Preferred Stock No Par Value
PreferredStockNoParValue
|
||
| CY2021Q4 | us-gaap |
Common Stock No Par Value
CommonStockNoParValue
|
||
| dei |
Entity File Number
EntityFileNumber
|
001-38891 | ||
| dei |
Entity Registrant Name
EntityRegistrantName
|
TransMedics Group, Inc. | ||
| dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
MA | ||
| dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
83-2181531 | ||
| dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
200 Minuteman Road | ||
| dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Andover | ||
| dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MA | ||
| dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
01810 | ||
| dei |
City Area Code
CityAreaCode
|
978 | ||
| dei |
Local Phone Number
LocalPhoneNumber
|
552-0900 | ||
| dei |
Trading Symbol
TradingSymbol
|
TMDX | ||
| dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
| dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | ||
| dei |
Entity Small Business
EntitySmallBusiness
|
false | ||
| dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
| dei |
Entity Shell Company
EntityShellCompany
|
false | ||
| CY2022Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
31924220 | |
| CY2022Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
204462000 | |
| CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
25580000 | |
| CY2021Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
66872000 | |
| CY2021Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
5934000 | |
| CY2021Q4 | us-gaap |
Inventory Net
InventoryNet
|
14859000 | |
| CY2021Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
5460000 | |
| dei |
Document Type
DocumentType
|
10-Q | ||
| CY2021Q4 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
16337000 | |
| CY2021Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
250000 | |
| CY2021Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
500000 | |
| CY2021Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
5847000 | |
| CY2021Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
6651000 | |
| CY2021Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
23238000 | |
| CY2021Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
35197000 | |
| CY2021Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
8604000 | |
| CY2021Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
27791615 | |
| CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-442446000 | |
| CY2021Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
25000000 | |
| CY2021Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2021Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2021Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | |
| CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
27791615 | |
| CY2021Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
510488000 | |
| us-gaap |
Operating Expenses
OperatingExpenses
|
42273000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-28100000 | ||
| us-gaap |
Interest Expense
InterestExpense
|
2896000 | ||
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-532000 | ||
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-3428000 | ||
| us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
19000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-31547000 | ||
| CY2022Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
187857000 | |
| us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-26000 | ||
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
0 | ||
| us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-36000 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-31583000 | ||
| tmdx |
Non Cash Interest And End Of Term Accretion Expense
NonCashInterestAndEndOfTermAccretionExpense
|
309000 | ||
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
381000 | ||
| us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
-1733000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
16287000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
6094000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
98000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-3534000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-8000 | ||
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
72000 | ||
| us-gaap |
Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
|
-76000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-41782000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-22216000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
9143000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
341000 | ||
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
10496000 | ||
| us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
66694000 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
76916000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
57277000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
19275000 | ||
| us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
509000 | ||
| tmdx |
Inventory Transfer To Property Plant And Equipment
InventoryTransferToPropertyPlantAndEquipment
|
935000 | ||
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
342000 | ||
| CY2022Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
204462000 | |
| CY2021Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
22495000 | |
| CY2022Q3 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
500000 | |
| CY2021Q3 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
500000 | |
| CY2022Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
204962000 | |
| CY2021Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
22995000 | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
1348000 | ||
| us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-493000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-2086000 | ||
| CY2022Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
204962000 | |
| CY2021Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
22995000 | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the valuation of inventory and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. As of the date of issuance of these unaudited consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities.<span style="Background-color:#FFFFFF;color:#212529;"> </span>Actual results may differ from those estimates or assumptions. </p> | ||
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Risk of Concentrations of Credit, Significant Customers and Significant Suppliers </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. As of September 30, 2022 and December 31, 2021, the Company had no allowance for credit losses. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant customers are those that accounted for 10% or more of the Company’s net revenue or accounts receivable. <span style="Background-color:#FFFFFF;color:#000000;">For the three months ended September 30, 2022, one customer accounted for</span> 13%<span style="Background-color:#FFFFFF;color:#000000;"> of net revenue. For the nine months ended September 30, 2022, one customer accounted for 15% of net revenue. For the three months ended September 30, 2021, two customers accounted for 16% and 12% of net revenue, respectively. For the nine months ended September 30, 2021, one customer accounted for 10% of net revenue. As of September 30, 2022, there were no customers that accounted for more than 10% of accounts receivable. As of December 31, 2021, two customers accounted for 21% and 15% of accounts receivable, respectively.</span> </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of the components and subassemblies included in the Company’s products are obtained from a sole source, a single source or a limited group of suppliers. Although the Company seeks to reduce dependence on those limited sources of suppliers and manufacturers, the partial or complete loss of certain of these sources could have a material adverse effect on the Company’s operating results, financial condition and cash flows and damage its customer relationships. </p> | ||
| CY2022Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
31933984 | |
| CY2022Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
31933984 | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
21056000 | ||
| CY2021Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-11725000 | |
| CY2021Q3 | us-gaap |
Interest Expense
InterestExpense
|
979000 | |
| us-gaap |
Interest Expense
InterestExpense
|
2719000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4893000 | ||
| CY2022Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2704000 | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
178882000 | ||
| CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
26080000 | |
| CY2021Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
5173000 | |
| CY2022Q3 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
60000000 | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-24658000 | ||
| CY2021Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-249000 | |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-4806000 | ||
| CY2021Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-12953000 | |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-29464000 | ||
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-31528000 | ||
| CY2021Q3 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
9000 | |
| us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
47000 | ||
| CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12962000 | |
| CY2021Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.47 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.03 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.14 | ||
| CY2021Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
27701252 | |
| CY2021Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
27701252 | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
28729649 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
28729649 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
27564589 | ||
| CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12962000 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-29511000 | ||
| CY2021Q3 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
3000 | |
| us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-95000 | ||
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
0 | ||
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
36000 | ||
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-10000 | ||
| us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-59000 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-29570000 | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2022-09-30 | ||
| CY2022Q3 | us-gaap |
Assets
Assets
|
274873000 | |
| CY2021Q4 | us-gaap |
Assets
Assets
|
134893000 | |
| CY2022Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3080000 | |
| CY2022Q3 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
15976000 | |
| CY2022Q3 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
226000 | |
| CY2022Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
1407000 | |
| CY2022Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
20689000 | |
| CY2022Q3 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
58540000 | |
| CY2022Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
7787000 | |
| CY2022Q3 | us-gaap |
Liabilities
Liabilities
|
87016000 | |
| CY2021Q4 | us-gaap |
Liabilities
Liabilities
|
67039000 | |
| CY2022Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
25000000 | |
| CY2022Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2022Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2022Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | |
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001756262 | ||
| us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | ||
| CY2022Q3 | us-gaap |
Preferred Stock No Par Value
PreferredStockNoParValue
|
||
| CY2022Q3 | us-gaap |
Common Stock No Par Value
CommonStockNoParValue
|
||
| us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | ||
| CY2021Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2022Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| dei |
Security12b Title
Security12bTitle
|
Common Stock, No Par Value | ||
| dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
| CY2022Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
22035000 | |
| CY2022Q3 | us-gaap |
Inventory Net
InventoryNet
|
18575000 | |
| CY2022Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
5514000 | |
| CY2022Q3 | us-gaap |
Assets Current
AssetsCurrent
|
250586000 | |
| CY2021Q4 | us-gaap |
Assets Current
AssetsCurrent
|
118705000 | |
| CY2022Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
18472000 | |
| CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
9841000 | |
| CY2022Q3 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
500000 | |
| CY2022Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
5315000 | |
| CY2022Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
660061000 | |
| CY2022Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-247000 | |
| CY2021Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-188000 | |
| CY2022Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-471957000 | |
| CY2022Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
187857000 | |
| CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
67854000 | |
| CY2022Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
274873000 | |
| CY2021Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
134893000 | |
| CY2022Q3 | us-gaap |
Revenues
Revenues
|
25683000 | |
| CY2021Q3 | us-gaap |
Revenues
Revenues
|
5370000 | |
| us-gaap |
Revenues
Revenues
|
62084000 | ||
| us-gaap |
Revenues
Revenues
|
20594000 | ||
| CY2022Q3 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
7568000 | |
| CY2021Q3 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
1597000 | |
| us-gaap |
Cost Of Revenue
CostOfRevenue
|
6421000 | ||
| CY2022Q3 | us-gaap |
Gross Profit
GrossProfit
|
18115000 | |
| CY2021Q3 | us-gaap |
Gross Profit
GrossProfit
|
3773000 | |
| us-gaap |
Gross Profit
GrossProfit
|
44569000 | ||
| us-gaap |
Gross Profit
GrossProfit
|
14173000 | ||
| CY2022Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
6808000 | |
| CY2021Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5163000 | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
15990000 | ||
| CY2022Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
16851000 | |
| CY2021Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
10335000 | |
| us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
48171000 | ||
| us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
26283000 | ||
| CY2022Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
23659000 | |
| CY2021Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
15498000 | |
| us-gaap |
Operating Expenses
OperatingExpenses
|
69227000 | ||
| CY2022Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-5544000 | |
| CY2022Q3 | us-gaap |
Interest Expense
InterestExpense
|
787000 | |
| CY2022Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-1076000 | |
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-2087000 | ||
| CY2022Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1863000 | |
| CY2021Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1228000 | |
| CY2022Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-7407000 | |
| CY2022Q3 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
19000 | |
| CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7426000 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-29511000 | ||
| CY2022Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.25 | |
| CY2022Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.25 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.14 | ||
| CY2022Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
30229936 | |
| CY2022Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
30229936 | |
| CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7426000 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-31547000 | ||
| CY2022Q3 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-41000 | |
| CY2022Q3 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
0 | |
| CY2021Q3 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
0 | |
| CY2022Q3 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
100000 | |
| CY2022Q3 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
59000 | |
| CY2021Q3 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
3000 | |
| CY2022Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-7367000 | |
| CY2021Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-12959000 | |
| CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
67854000 | |
| CY2022Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
202000 | |
| CY2022Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
203000 | |
| CY2022Q1 | tmdx |
Adjustments To Common Stock Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToCommonStockShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
2310000 | |
| CY2022Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-24000 | |
| CY2022Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-73000 | |
| CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10562000 | |
| CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
59910000 | |
| CY2022Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
237000 | |
| CY2022Q2 | tmdx |
Adjustments To Common Stock Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToCommonStockShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
2316000 | |
| CY2022Q2 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-30000 | |
| CY2022Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
9000 | |
| CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-11523000 | |
| CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
50919000 | |
| CY2022Q3 | tmdx |
Discounts And Issuance Costs
DiscountsAndIssuanceCosts
|
676000 | |
| CY2022Q3 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
139854000 | |
| CY2022Q3 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
1441000 | |
| CY2022Q3 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
306000 | |
| CY2022Q3 | tmdx |
Adjustments To Common Stock Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToCommonStockShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
2704000 | |
| CY2022Q3 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-41000 | |
| CY2022Q3 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
100000 | |
| CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7426000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
103891000 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
372000 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
211000 | |
| CY2021Q1 | tmdx |
Adjustments To Common Stock Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToCommonStockShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
1112000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-2000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
8000 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7917000 | |
| CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
97675000 | |
| CY2021Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
213000 | |
| CY2021Q2 | tmdx |
Adjustments To Common Stock Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToCommonStockShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
1808000 | |
| CY2021Q2 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-27000 | |
| CY2021Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-18000 | |
| CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10668000 | |
| CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
88983000 | |
| CY2021Q3 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
344000 | |
| CY2021Q3 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
208000 | |
| CY2021Q3 | tmdx |
Adjustments To Common Stock Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToCommonStockShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
1973000 | |
| CY2021Q3 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
3000 | |
| CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12962000 | |
| CY2021Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
78549000 | |
| us-gaap |
Profit Loss
ProfitLoss
|
-29511000 | ||
| us-gaap |
Profit Loss
ProfitLoss
|
-31547000 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
2193000 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1351000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
7330000 | ||
| us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-575000 | ||
| us-gaap |
Loss On Sale Of Investments
LossOnSaleOfInvestments
|
107000 | ||
| tmdx |
Non Cash Interest And End Of Term Accretion Expense
NonCashInterestAndEndOfTermAccretionExpense
|
401000 | ||
| tmdx |
Non Cash Lease Expense
NonCashLeaseExpense
|
532000 | ||
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
1075000 | ||
| us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
-587000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-2650000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
3964000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1392000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1226000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
2356000 | ||
| us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
590000 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
86310000 | ||
| us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
58509000 | ||
| us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
36050000 | ||
| tmdx |
Proceeds From Issuance Of Common Stock In Initial Public Offering Net Of Underwriting Discounts And Commissions And Issuance Costs Paid
ProceedsFromIssuanceOfCommonStockInInitialPublicOfferingNetOfUnderwritingDiscountsAndCommissionsAndIssuanceCostsPaid
|
140014000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1880000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
929000 | ||
| us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
419000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
164862000 | ||
| us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-1475000 | ||
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
25081000 | |
| tmdx |
Inventory Transfer To Property Plant And Equipment
InventoryTransferToPropertyPlantAndEquipment
|
2055000 | ||
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
926000 | ||
| CY2022Q3 | tmdx |
Offering Cost Included In Accounts Payable And Accrued Expenses
OfferingCostIncludedInAccountsPayableAndAccruedExpenses
|
160000 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-29500000 | ||
| CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-44200000 | |
| CY2022Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-472000000.0 | |
| CY2022Q3 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
204500000 | |
| CY2022Q3 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
9439000 | |
| CY2022Q3 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
0 | |
| CY2021Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
0 | |
| CY2022Q3 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
182091000 | |
| CY2021Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
78041000 | |
| CY2022Q3 | us-gaap |
Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
|
1600000 | |
| CY2021Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
7274000 | |
| CY2022Q3 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
1721000 | |
| CY2021Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
1932000 | |
| CY2022Q3 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
7415000 | |
| CY2021Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
5653000 | |
| CY2022Q3 | us-gaap |
Inventory Net
InventoryNet
|
18575000 | |
| CY2021Q4 | us-gaap |
Inventory Net
InventoryNet
|
14859000 | |
| tmdx |
Inventory Transfer To Property Plant And Equipment
InventoryTransferToPropertyPlantAndEquipment
|
2100000 | ||
| tmdx |
Inventory Transfer To Property Plant And Equipment
InventoryTransferToPropertyPlantAndEquipment
|
900000 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3407199 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2826044 | ||
| CY2022Q3 | us-gaap |
Marketable Securities
MarketableSecurities
|
0 | |
| CY2021Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
66908000 | |
| CY2021Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
36000 | |
| CY2021Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
66872000 | |
| CY2022Q3 | tmdx |
Accrued Research Development And Clinical Trials Expenses Current
AccruedResearchDevelopmentAndClinicalTrialsExpensesCurrent
|
2735000 | |
| CY2021Q4 | tmdx |
Accrued Research Development And Clinical Trials Expenses Current
AccruedResearchDevelopmentAndClinicalTrialsExpensesCurrent
|
4567000 | |
| CY2022Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
6064000 | |
| CY2022Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1424000 | |
| CY2021Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1973000 | |
| CY2022Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
5753000 | |
| CY2021Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
4624000 | |
| CY2022Q3 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
15976000 | |
| CY2021Q4 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
16337000 | |
| CY2021Q3 | tmdx |
Customer Payments Recorded As Operating Expenses
CustomerPaymentsRecordedAsOperatingExpenses
|
400000 | |
| tmdx |
Customer Payments Recorded As Operating Expenses
CustomerPaymentsRecordedAsOperatingExpenses
|
1600000 | ||
| CY2022Q3 | us-gaap |
Revenues
Revenues
|
25683000 | |
| CY2021Q3 | us-gaap |
Revenues
Revenues
|
5370000 | |
| CY2021Q4 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
35000000 | |
| CY2022Q3 | tmdx |
Long Term Debt Noncurrent Before Debt Discount And Accrued Payments
LongTermDebtNoncurrentBeforeDebtDiscountAndAccruedPayments
|
60000000 | |
| CY2021Q4 | tmdx |
Long Term Debt Noncurrent Before Debt Discount And Accrued Payments
LongTermDebtNoncurrentBeforeDebtDiscountAndAccruedPayments
|
35000000 | |
| CY2022Q3 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
1460000 | |
| CY2021Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
511000 | |
| CY2021Q4 | us-gaap |
Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid
DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
|
708000 | |
| CY2022Q3 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
58540000 | |
| CY2021Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
35197000 | |
| CY2021Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1973000 | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7330000 | ||
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4893000 | ||
| CY2022Q3 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
21100000 | |
| us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y7M6D | ||
| us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
0 | ||
| CY2021 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
0 | |
| CY2021Q1 | us-gaap |
Recorded Unconditional Purchase Obligation
RecordedUnconditionalPurchaseObligation
|
9500000 | |
| CY2021Q1 | tmdx |
Recorded Unconditional Purchase Commitment Maturity Year And Month
RecordedUnconditionalPurchaseCommitmentMaturityYearAndMonth
|
2029-12 | |
| CY2022Q3 | tmdx |
Unconditional Purchase Obligation Remaining Amount
UnconditionalPurchaseObligationRemainingAmount
|
8000000.0 | |
| us-gaap |
Revenues
Revenues
|
62084000 | ||
| us-gaap |
Revenues
Revenues
|
20594000 | ||
| CY2022Q3 | us-gaap |
Revenues
Revenues
|
25683000 | |
| CY2021Q3 | us-gaap |
Revenues
Revenues
|
5370000 | |
| us-gaap |
Revenues
Revenues
|
62084000 | ||
| us-gaap |
Revenues
Revenues
|
20594000 | ||
| CY2022Q3 | us-gaap |
Contract With Customer Asset Net
ContractWithCustomerAssetNet
|
0 | |
| CY2021Q4 | us-gaap |
Contract With Customer Asset Net
ContractWithCustomerAssetNet
|
0 | |
| us-gaap |
Revenue Performance Obligation Description Of Timing
RevenuePerformanceObligationDescriptionOfTiming
|
The Company generally satisfies performance obligations within one year of the contract inception date. | ||
| us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | ||
| CY2022Q3 | us-gaap |
Noncurrent Assets
NoncurrentAssets
|
18472000 | |
| CY2021Q4 | us-gaap |
Noncurrent Assets
NoncurrentAssets
|
9841000 | |
| CY2022Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
24303000 | |
| CY2021Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
5413000 | |
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
60704000 | ||
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
21717000 | ||
| CY2022Q3 | tmdx |
Clinical Trial Expense
ClinicalTrialExpense
|
-1380000 | |
| CY2021Q3 | tmdx |
Clinical Trial Expense
ClinicalTrialExpense
|
43000 | |
| tmdx |
Clinical Trial Expense
ClinicalTrialExpense
|
-1380000 | ||
| tmdx |
Clinical Trial Expense
ClinicalTrialExpense
|
1123000 | ||
| CY2022Q3 | us-gaap |
Revenues
Revenues
|
25683000 | |
| CY2021Q3 | us-gaap |
Revenues
Revenues
|
5370000 | |
| us-gaap |
Revenues
Revenues
|
62084000 | ||
| us-gaap |
Revenues
Revenues
|
20594000 | ||
| CY2022Q3 | tmdx |
Customer Payments Recorded As Operating Expenses
CustomerPaymentsRecordedAsOperatingExpenses
|
500000 | |
| tmdx |
Customer Payments Recorded As Operating Expenses
CustomerPaymentsRecordedAsOperatingExpenses
|
1000000.0 |
